CITIUS ONCOLOGY, INC.
About CITIUS ONCOLOGY, INC.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2026
- $5.6M
- Net income
- -$24.8M
- Total assets
- $100.9M
- Market cap
- $72.5M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $23.5M
- Operating income
- -$23.5M
- Income tax
- $1.1M
- Net income
- -$24.8M
- EPS (basic)
- $-0.34
- EPS (diluted)
- $-0.34
Balance sheet
- Total assets
- $100.9M
- Current assets
- $27.5M
- Total liabilities
- $56.1M
- Current liabilities
- $49.5M
- Shareholders’ equity
- $44.9M
Cash flow
- Operating cash flow
- -$5.5M
- Investing cash flow
- -$5.8M
- Financing cash flow
- $15.2M
- Net cash flow
- $3.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $72.5M
- EPS (diluted)
- $-0.34
- Shares outstanding
- 90.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 13, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $24.8M in FY2026.
- Trading 85% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CITIUS ONCOLOGY, INC..
Write a review
News about CITIUS ONCOLOGY, INC.
News & sentiment via Polygon.io
